The PPARγ Agonist Efatutazone Increases the Spectrum of Well-Differentiated Mammary Cancer Subtypes Initiated by Loss of Full-Length BRCA1 in Association with TP53 Haploinsufficiency

Peroxisome proliferator–activated receptor gamma (PPARγ) agonists have anticancer activity and influence cell differentiation. We examined the impact of the selective PPARγ agonist efatutazone on mammary cancer pathogenesis in a mouse model of BRCA1 mutation. Mice with conditional loss of full-lengt...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Nakles, Rebecca E., Kallakury, Bhaskar V.S., Furth, Priscilla A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society for Investigative Pathology 2013
Ämnen:
Short Communication
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3668033/
https://ncbi.nlm.nih.gov/pubmed/23664366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajpath.2013.02.006
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk